Table 2.

Meta-analysis results of ADRs and TRAEs (Figures S1–S11).

Outcomes	Trials	Events/Total	Events/Total	Statistic method	Odds Ratio, 95%CI	I2	p
Neutropenia (Figure S1)	32	302/971	299/967	Fixed-effects model	0.98 [0.79, 1.21]	0%	p = 0.83
Thrombocytopenia (Figure S2)	28	187/875	178/868	Fixed-effects model	1.04 [0.80, 1.36]	0%	p = 0.76
Anemia (Figure S3)	10	49/337	40/339	Fixed-effects model	1.29 [0.80, 2.09]	0%	p = 0.30
Cardiotoxicity (Figure S4)	21	37/671	27/672	Fixed-effects model	1.39 [0.84, 2.31]	0%	p = 0.20
Hepatotoxicity (Figure S5)	28	91/898	95/900	Fixed-effects model	1.07 [0.77, 1.48]	0%	p = 0.68
Nephrotoxicity (Figure S6)	28	91/898	85/900	Fixed-effects model	1.07 [0.77, 1.48]	0%	p = 0.68
Gastrointestinal reactions (Figure S7)	49	436/1554	397/1538	Fixed-effects model	1.14 [0.95, 1.36]	0%	p = 0.16
Chest pain (Figure S8)	12	51/316	50/321	Fixed-effects model	1.01 [0.63, 1.60]	0%	p = 0.98
Fever (Figure S9)	20	67/578	68/573	Fixed-effects model	0.98 [0.68, 1.41]	0%	p = 0.89
Alopecia (Figure S10a)	2	3/63	4/61	Fixed-effects model	1.22 [0.33, 4.54]	0%	p = 0.76
Neurotoxicity (Figure S10b)	5	8/175	8/173	Fixed-effects model	0.98 [0.36, 2.65]	0%	p = 0.96
Rash (Figure S10c)	5	17/193	11/186	Fixed-effects model	1.57 [0.71, 3.50]	0%	p = 0.27
Hypertension (Figure S10d)	3	5/92	0/84	Fixed-effects model	4.13 [0.68, 25.10]	0%	p = 0.12
Hamorrhage (Figure S10e)	2	4/70	1/66	Fixed-effects model	2.95 [0.45, 19.38]	0%	p = 0.26
Thoracentesis-related adverse events (Figure S11)	9	0/303	0/296	No	Not estimable	No	No
Treatment-related mortality (TRM) (Figure S11)	6	0/145	0/137	No	Not estimable	No	No

ADRs, adverse drug reactions; TRAEs, thoracentesis-related adverse events; CI, confidence interval.